Geode Capital Management LLC Sells 40,053 Shares of TG Therapeutics, Inc. $TGTX

Geode Capital Management LLC trimmed its position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) by 1.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,403,866 shares of the biopharmaceutical company’s stock after selling 40,053 shares during the period. Geode Capital Management LLC owned approximately 2.14% of TG Therapeutics worth $101,483,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of TGTX. Congress Asset Management Co. acquired a new stake in TG Therapeutics in the 4th quarter valued at approximately $57,307,000. Nordea Investment Management AB acquired a new stake in TG Therapeutics in the 4th quarter valued at approximately $2,356,000. Penn Capital Management Company LLC grew its holdings in TG Therapeutics by 17.6% in the 3rd quarter. Penn Capital Management Company LLC now owns 521,260 shares of the biopharmaceutical company’s stock valued at $18,877,000 after buying an additional 77,895 shares during the last quarter. Public Sector Pension Investment Board grew its holdings in TG Therapeutics by 14.5% in the 3rd quarter. Public Sector Pension Investment Board now owns 529,271 shares of the biopharmaceutical company’s stock valued at $19,120,000 after buying an additional 66,911 shares during the last quarter. Finally, JPMorgan Chase & Co. grew its holdings in TG Therapeutics by 56.1% in the 3rd quarter. JPMorgan Chase & Co. now owns 227,934 shares of the biopharmaceutical company’s stock valued at $8,234,000 after buying an additional 81,907 shares during the last quarter. 58.58% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

TGTX has been the topic of a number of research analyst reports. Wall Street Zen lowered TG Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, February 14th. HC Wainwright reaffirmed a “buy” rating and issued a $70.00 target price on shares of TG Therapeutics in a report on Wednesday, May 27th. Weiss Ratings raised TG Therapeutics from a “hold (c)” rating to a “hold (c+)” rating in a report on Friday, May 1st. Finally, Zacks Research raised TG Therapeutics from a “strong sell” rating to a “hold” rating in a report on Monday, June 1st. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and three have given a Hold rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $52.50.

TG Therapeutics Price Performance

Shares of TGTX stock opened at $40.16 on Friday. The stock has a 50 day moving average of $37.05 and a two-hundred day moving average of $32.59. The company has a current ratio of 5.81, a quick ratio of 5.12 and a debt-to-equity ratio of 1.28. TG Therapeutics, Inc. has a 12 month low of $25.28 and a 12 month high of $44.65. The company has a market capitalization of $6.15 billion, a P/E ratio of 14.04 and a beta of 1.68.

TG Therapeutics (NASDAQ:TGTX) last announced its quarterly earnings data on Wednesday, May 6th. The biopharmaceutical company reported $0.12 EPS for the quarter, missing analysts’ consensus estimates of $0.23 by ($0.11). The firm had revenue of $204.92 million during the quarter, compared to the consensus estimate of $200.33 million. TG Therapeutics had a return on equity of 88.73% and a net margin of 65.95%.TG Therapeutics’s revenue was up 69.5% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.03 EPS. As a group, equities analysts expect that TG Therapeutics, Inc. will post 1.51 EPS for the current year.

TG Therapeutics Company Profile

TG Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in New York City that specializes in developing targeted therapies for hematological malignancies and autoimmune diseases. The company’s research strategy focuses on the modulation of B-cell biology through novel antibody and small‐molecule agents. Since its founding in 2003, TG Therapeutics has built a diversified portfolio aimed at addressing unmet medical needs in oncology and immunology.

In December 2022, TG Therapeutics achieved its first commercial milestone when ublituximab-xiiy (marketed as Briumvi® in collaboration with Biogen) received U.S.